Repeated dosing study, 1996
A trial in six subjects found hexarelin and GHRH synergistic on first administration, but the synergy was lost when dosing was repeated over time. Reported in the cited paper.
SourceResearch Use Only. Products listed are not for human or animal consumption. Statements have not been evaluated by the FDA.View full disclaimers →

Hexarelin is a synthetic hexapeptide growth hormone secretagogue that produces the strongest pulse in its class. It also desensitises fastest, with the response falling within two to four weeks of continuous use in the published research.
Supplier listings
Form
Show prices as
Size
12 listings · Hexarelin
In stock10mgseen 7w ago
In stock2mgseen 2w ago
In stock5mgseen 7w ago
In stock5mgseen 7w ago
In stock5mgseen 4w ago
In stock5mgseen 7w ago
In stock5mgseen 7w ago
Out of stock5mgseen 7w ago
Out of stock5mgseen 5w ago
Out of stock5mgseen 7w ago
Overview
Hexarelin is a synthetic hexapeptide growth hormone secretagogue that produces the strongest pulse in its class. It also desensitises fastest, with the response falling within two to four weeks of continuous use in the published research.
What the research reports
Outcomes described across the published Hexarelin literature and ongoing study. Read each as research context rather than a promised personal result.
Strongest GH pulse in class
Produces a larger growth hormone response than other peptides in the ghrelin receptor family, which is its defining pharmacological characteristic within the class.
Pituitary reserve testing
A 1999 cohort found the hexarelin test reliable for screening growth hormone deficiency, though unreliable for ACTH and cortisol reserve. Reported in research settings.
Cushing's differentiation
A 2000 trial reported the hexarelin test effectively separated Cushing's disease from alcohol induced pseudo-Cushing's syndrome. Reported in research settings.
Cardiac research interest
A separate research line explores cardioprotective effects through CD36 signalling that appear independent of growth hormone release. Reported in research settings.
Metabolic pathway research
Work describes CD36 and PPAR gamma activation linked to insulin resistance and lipid handling in metabolic disorder models. Reported in research settings.
Clinical evidence
The published Hexarelin record, labeled by strength so you can see what is settled and what is still emerging.
A trial in six subjects found hexarelin and GHRH synergistic on first administration, but the synergy was lost when dosing was repeated over time. Reported in the cited paper.
SourceA trial in 29 elderly subjects reported that adding GHRH or arginine restored the blunted growth hormone response seen with hexarelin alone. Reported in the cited paper.
SourceA cohort of 19 patients with pituitary disease found the hexarelin test reliable for screening growth hormone deficiency but not for ACTH or cortisol reserve. Reported in the cited paper.
SourceInteractions
Questions